Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Bristol-Myers Squibb

Opdivo, Eliquis, and Hep C franchise drives growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb
 
1Q Revenues: $4.4 Billion (+9%)

1Q Earnings: $1.2 billion (flat)

Comments: Opdivo sales were $704 million in the quarter. Sprycel sales were $407 million, up 9%. Yervoy sales were down 19% to $263 million. Eliquis sales were $734 million in the quarter. Orencia sales were up 19% to $475 million. Revenues include the impact of the transfer of Erbitux and Abilify rights to ImClone and Otsuka, respectively. Hepatitis C Franchise sales were up 62% to $427 million. Reyataz and Sustiva sales were down 25% and 6% respectively.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters